Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2023-09-13 Share Issue/Capital Cha…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Share Issue/Capital Change Classification · 95% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (L.233-8 II du Code de commerce and 223-16 du Règlement Général de l'Autorité des Marchés Financiers - AMF). The core content is a table showing the total number of shares and voting rights as of August 31, 2023. This type of mandatory periodic disclosure regarding the total share capital and voting rights structure is a specific regulatory filing requirement, often related to major shareholding notifications or capital structure updates, but the most fitting category for mandatory periodic disclosure of voting rights/share count is often captured under general regulatory announcements or specific shareholding rules. Given the options, this is a mandatory disclosure about the capital structure and voting rights, which is a specific type of regulatory filing. It is not a general earnings release (ER), an interim report (IR), or a major shareholding notification (MRQ) which usually reports a change crossing a threshold. Since it is a mandatory, periodic disclosure of the total capital structure as required by the AMF, it fits best under the general regulatory filing category (RNS) or potentially a specific capital/share announcement. However, since it is a routine monthly update on the total number of shares and voting rights, which is a specific regulatory requirement, and doesn't fit perfectly into the other specific categories like DIV, SHA, or MRQ (which implies crossing a threshold), RNS (Regulatory Filings) serves as the appropriate fallback for mandatory, non-standardized disclosures. Upon re-evaluation, this specific disclosure about the total number of shares and voting rights is a very common regulatory filing in France. While RNS is a fallback, the content is highly specific to capital structure reporting. Since there isn't a dedicated 'Share Capital Disclosure' code, and it's not a transaction (POS) or a general share issue (SHA), RNS is the most appropriate catch-all for mandatory regulatory updates that don't fit elsewhere, although it is very close to MRQ's scope. Given the strict definitions, RNS is the safest classification for a routine regulatory update not covered by the other specific codes.
2023-09-13 French
Voting Rights and Shares Capital of the Company
Share Issue/Capital Change Classification · 95% confidence The document is a press release titled "VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY" and explicitly references French Commercial Code articles regarding the disclosure of the total number of voting rights and shares outstanding on a monthly basis (August 31, 2023 data provided). This type of regular disclosure regarding the capital structure and voting rights, often mandated by local regulators (here, the AMF), does not fit neatly into the primary financial report categories (10-K, IR, ER). It is a specific regulatory update concerning share structure. While it relates to capital, it is not a fundraising announcement (CAP) or a major shareholding notification (MRQ) which usually relates to crossing ownership thresholds. Since it is a specific, recurring regulatory disclosure that doesn't fit the other specific categories, it falls best under the general Regulatory Filings category (RNS), as it is a mandatory public disclosure of share capital figures.
2023-09-13 English
Franchissement de seuil
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissement de seuil (article L. 233-7 du code de commerce)" which translates to 'Declaration of crossing a threshold (Article L. 233-7 of the Commercial Code)'. It explicitly states that Baillie Gifford & Co. crossed the 5% threshold of voting rights in NANOBIOTIX on September 7, 2023. This type of filing, reporting changes in significant share ownership by an entity, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is short and contains specific regulatory reporting details, confirming it is the notification itself, not an announcement of a report.
2023-09-13 French
Franchissement de seuil
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissement de seuil (article L. 233-7 du code de commerce)" which translates to 'Declaration of crossing a threshold (Article L. 233-7 of the Commercial Code)'. It details that Baillie Gifford & Co. crossed the 5% ownership threshold of NANOBIOTIX shares on August 31, 2023. This type of filing, reporting changes in significant share ownership that cross regulatory thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is short and contains specific regulatory reporting details, confirming it is a direct filing rather than an announcement of a report.
2023-09-07 French
NANOBIOTIX renforce ses capacités de développement international avec la nomination d’un leader experimenté de l’industrie, le Dr. Louis Kayitalire, au poste de Chief medical officer
Board/Management Information Classification · 98% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a significant management change: the appointment of Dr. Louis Kayitalire as Chief Medical Officer. This content directly aligns with the definition of Board/Management Information, which covers announcements of changes in senior management. The document is a formal announcement, not a comprehensive financial report (like 10-K or IR) or a transcript of a call. Therefore, the appropriate classification is MANG.
2023-09-05 French
NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer
Board/Management Information Classification · 99% confidence The document is explicitly titled '# *PRESS RELEASE*' and announces the appointment of a new Chief Medical Officer (Dr. Louis Kayitalire) and provides updates on the company's lead product candidate (NBTXR3) and recent agreements. This type of announcement, focusing on executive changes and operational updates, is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is a press release announcing key personnel and operational news, and not a full financial report (10-K, IR) or a transcript (CT), the most fitting category is Earnings Release (ER), as these often accompany quarterly results or significant corporate events. However, given the primary focus is on a management appointment rather than financial figures, it aligns very closely with Board/Management Information (MANG). Since the document is a formal press release announcing a key executive hire, MANG is the most precise fit, although ER is also plausible if this release accompanied financial results. Given the strong emphasis on the CMO appointment, MANG is selected.
2023-09-05 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.